Nektar Therapeutics announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255, a novel polymer-conjugated human IL-15, on the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model and on CD8+ T effector cell (Tcell) and natural killer (NK) cell proliferation in non-human primates. The data from this publication demonstrate that NKTR-255 not only enhanced in vivo proliferation and accumulation of T and NK cells in non-human primates, but also demonstrated enhanced in vivo antitumor efficacy of human CD19 CAR-T in lymphoma-bearing immunodeficient mice. Key findings are summarized below: Serum IL-15 concentration is independently associated with longer CD19 CAR-T persistence in humans, NKTR-255 promotes CD8+ effector and memory T and NK cell accumulation in non-human primates, NKTR-255 enhances proliferation and survival of human CD19 CAR-T at low target cell abundance and NKTR-255 enhances accumulation and efficacy of human CD19 CAR-T in lymphoma bearing immunodeficient mice.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 USD | -4.35% | 0.00% | +133.63% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+133.63% | 242M | |
+24.62% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.30% | 233B | |
+5.29% | 201B | |
-10.06% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- NKTR Stock
- News Nektar Therapeutics
- Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, A Novel Polymer-Conjugated Human IL-15, Improves Efficacy of CD19-Targeted CAR-T Cell Immunotherapy